MARKET-THE EPINEX SIMPLYSURE PT-INR BLOOD COAGULATION TEST

THE EPINEX SIMPLYSURE PT-INR COAGULATION TEST

Market Size

 

                                     

                                  Atrial Fibrillation and Stroke in the United States

 

 

 

 

 

 

 

Condition

Prevalence

Atrial Fibrillation

3 million cases/year (Mayo Clinic)

Stroke

~800,000 per year

15%-20% attribute to AF

6.4 million total adult stroke cases

Receiving a stent

~600,000 per year 

(patients receiving a stent

must have anti-coagulation

therapy)

 

 

People taking blood-thinning medicines such as Warfarin need regular blood tests to check how well the medicines are working. The most common test is the PT/INR test (Prothrombin Time/International Normalized Ratio). People taking Warfarin must have the effect of drug monitored regularly, as often as once a week.

 

At present, all PT/INR testing, whether Point-of-Care or self-testing, requires an expensive reader device in addition to the actual test strips. Even though medical authorities are calling for increased self-testing, in 2011 only 13% of coagulation testing performed worldwide was self-testing.

 

The Self-Testing Market Opportunity:

  • 20 million existing Warfarin users in the United States.

–Estimated 2 million new users each year

  • Recommended weekly testing.

–Equates to a potential 1 billion tests each year.

 

Epinex SimplySure PT-INR Advantage Over the Competition:

  • SimplySure PT-INR does not require complex and costly instrumentation for testing.

  • All competition requires upfront instrument/device cost >$900.

  • Simplicity and cost effectiveness of SimplySure PT-INR enables easy physician office or self-testing without need for additional infrastructure or patient assistance.

  • Disposable test design facilitates INR monitoring at any time any place.

     

     

     

     

     

     

     

     

     

Target Users

 

Professional                                                                 Consumers        

• Pharmacies

• Specialty Healthcare Providers

• Home Healthcare

• Home Testing Supplies

• Retail Organizations

• Physician office Labs

• Emergency Rooms

• Home Healthcare

• Nursing Homes

• Hospitals

• Small Reference Lab

• Stat Locations

• Research & Biotechnology

•Defense & other Government Agencies

* This product is under development and is intended for information and evaluation purposes only. It is NOT APPROVED by the USFDA.

   Company                       Product                               Technology                           Markets                                  Investor Relations

   Company Overveiw           G1A Test                                Overview                                Overview                                  Shareholder Website

   Management                   ACR Test                                 G1A Test                                G1A Test                                  Corporate Profile & Governance

   Advisory Board                SimplySure PT-INR Test             ACR Test                                ACR Test                           

                                                                                    SimplySure PT-INR Test            SimplySure PT-INR Test       

                                                                                    Intellectual Property                                                      

   

  Publications                                    Contact               

  Corporate Information Series                                  

  Scientific Reviews  

                                                                                                                                                                              

                              

 

 

 

 

 

© 2016 by Epinex Diagnostics Inc

Epinex-G1A-Glycated Albumin-Monthly Diabetes Test

FOLLOW US:

  • w-facebook
  • Twitter Clean
  • White LinkedIn Icon